Focus on tumor prevention and control, experts call for: early screening, early diagnosis and early treatment of liver cancer should be concerned by the whole society

"The early prevention, early screening, early diagnosis, and early treatment of tumors are not only the tasks of scientists, but also things that the whole society should pay attention to.
" Wang Hongyang, academician of the Chinese Academy of Engineering and director of the National Liver Cancer Science Center, pointed out.

On April 17, sponsored by Eastern Hepatobiliary Surgery Hospital of Naval Military Medical University/National Liver Cancer Science Center, co-organized by Fujian Cancer Hospital and Mengchao Hepatobiliary Hospital of Fujian Medical University, undertook by Herui Gene, supported by People’s Daily Health Client and Chief Media of Health Times The National Multi-center Prospective Liver Cancer Very Early Warning Screening Project (PreCar) Progress Meeting and the First Tumor Early Diagnosis and Treatment Precision Prevention and Control Summit Forum was held in Fuzhou.
Academician Wang Hongyang shared at the meeting, "I am returning from studying in Germany.
Since then, I have been appealing, hoping to strengthen the early screening and diagnosis of malignant tumors, and not to concentrate all our energy on the treatment of mid- to late-stage tumors.
Although the treatment of these patients is also a very important task for us, we should prevent more patients from suffering The transformation of chronic inflammation into malignant diseases and blocking the process of inflammatory cancer transformation is the most effective way for us to deal with the challenge.
"

Promote early screening, diagnosis and treatment of liver cancer

Blocking the transformation process of inflammatory cancer is the most effective way to prevent and treat tumors

In recent years, the incidence and mortality of cancer in my country have both been on the rise.

At the meeting, Professor Hou Jinlin, director of the Department of Infectious Medicine, Nanfang Hospital of Southern Medical University, proposed a "pyramid" strategy for liver cancer screening.

Has a sensitivity of 95.

In 2018, led by Academician Wang Hongyang from Eastern Hepatobiliary Surgery Hospital of Naval Military Medical University/National Liver Cancer Science Center, and Professor Hou Jinlin from Southern Hospital of Southern Medical University, Herui Gene led the implementation of a prospective clinical project for early screening of liver cancer with the participation of nearly 20 domestic clinical centers.

In February this year, the international journal Cell Research published the first clinical research results based on the PreCar project.

"The two-wheel drive of'scientific research + clinical practice', exploring and solving all the pain points of screening, diagnosis, treatment and prognosis" is the follow-up plan and goal of Herui Gene.

Among them, primary liver cancer is one of the common malignant tumors in my country, and its onset is closely related to liver cirrhosis.

At the same time, at the meeting, the project team announced new trends including "cfDNA-based auxiliary diagnosis of benign and malignant liver cirrhotic nodules" and "live and postoperative cfDNA dynamic monitoring of liver cancer.